Download now: Oil Price Outlook 2024

How to Earn a 37% Gain in 7 Hours

Jeff Siegel

Written By Jeff Siegel

Updated March 25, 2024

Last week, I shared this chart with you …

mnmd2

At one point, this stock was up 86.8% in just over an hour. 

This is what happened to MindMed (NASDAQ: MNMD) after it was announced that the company had received breakthrough designation status from the FDA for its treatment for generalized anxiety disorder.

If you’re unfamiliar, the FDA grants breakthrough status for drugs that treat life-threatening conditions, and clinical evidence shows that those drugs demonstrate substantial improvement over currently available treatments. 

Now what made this particularly interesting was that MindMed’s new medication is an EN-23 medication.

If you’re unfamiliar, EN-23 is a valuable class of molecules that drastically improves brain function.  

It’s actually one of the biggest breakthroughs medical science has seen in 50 years, because not only can it treat mental health conditions such as depression, anxiety, PTSD and addiction, it also has the ability to help you lose weight, treat chronic pain and even extend your lifespan by up to 20 years.

Now over the past few weeks, three things have happened that you absolutely need to know about.

First, the FDA granted breakthrough status for MindMed, which sent the stock soaring more than 58% in just one hour.

Second, an analyst at J.P. Morgan let it slip that the behemoth investment bank (with assets in excess of $2.5 trillion) is now in dialogue with a number of companies developing new EN-23 treatments for mental health conditions.

And third, the FDA announced another breakthrough therapy designation for another EN-23 company called Cybin (NYSE: CYBN).

Here’s what happened right after that announcement …

cybn

Less than a week prior to this announcement, I told you the following …

… at the moment, there are two EN-23 companies in particular that are next in line for breakthrough status designation from the FDA.  And when that happens, expect to see the same result we saw last week with MindMed.

Cybin was one of those two stocks.

That’s two EN-23 stocks getting FDA breakthrough therapy designations within two weeks.

The third, dear reader, is coming up next.

And I imagine you’d like to know the name of this stock before that happens.

After all, the first two I told you about delivered a 58% gain in one hour and a 37.3% gain in just under 7 hours. 

There’s no doubt in my mind that this next EN-23 stock will be the next to get breakthrough therapy designation, and I want to make sure you own shares of this thing before that happens.

That’s why I put together this short investment note which includes all the information you need to know about this stock so you can grab shares before the FDA grants it breakthrough therapy designation. 

I also have a more in-depth presentation that also includes information on two more EN-23 stocks that I believe are in line for massive gains this year.  You can download that for free, here

Given how fast the FDA is granting breakthrough therapy designations for these EN-23 companies, I highly recommend you buy shares of the company I believe will be the next to get this designation. Because mark my words: it’s going to happen fast!

To a new way of life and a new generation of wealth…

Jeff Siegel Signature

Jeff Siegel

follow basicCheck us out on YouTube!

follow basic@JeffSiegel on Twitter

Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.

Angel Pub Investor Club Discord - Chat Now

Jeff Siegel Premium

Introductory

Hydrogen Fuel Cells: The Downfall of Tesla?

Lithium has been the front-runner in the battery technology market for years, but that is all coming to an end. Elon Musk is against them, but Jeff Bezos is investing heavily in them. Hydrogen Fuel Cells will turn the battery market upside down and we've discovered a tiny company that is going to make it happen...

Sign up to receive your free report. After signing up, you'll begin receiving the Energy and Capital e-letter daily.